H. Lundbeck A/S

143 articles about H. Lundbeck A/S

• H. Lundbeck A/S To Research Link Between Immune System And Brain Diseases

  12/22/2014

• H. Lundbeck A/S Will Halt Studies Into Vampire Bat Saliva Drug

  12/19/2014

• Ossianix Expands And Extends Its Research Collaboration With H. Lundbeck A/S On CNS Therapeutics

  12/16/2014

• Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S Release: U.S. FDA Accepts For Review Supplemental New Drug Application For Deltoid Administration Of Abilify Maintena® (Aripiprazole) Extended-Release Injectable Suspension

  12/15/2014

• Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S’s Brexpiprazole Demonstrates Statistically Significant Effects In New Phase 3 Studies In Adult Patients With Schizophrenia Presented At The American College Of Neuropsychopharmacology Annual Meeting

  12/11/2014

• Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S Present Phase 3 Data On Brexpiprazole As Adjunctive Therapy In Adult Patients With Major Depression At The American College Of Neuropsychopharmacology Annual Meeting

  12/10/2014

• H. Lundbeck A/S Release: New Study: Art Therapy May Build Self-Esteem In People Living With Epilepsy

  12/8/2014

• H. Lundbeck A/S Release: Five-Year Data From SABRIL® (Vigabatrin) Registry Presented At American Epilepsy Society Annual Meeting

  12/8/2014

• Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S Release: Aripiprazole Once-Monthly Injectable Shows Superior Effectiveness To Paliperidone Palmitate Once-Monthly Injectable On Quality Of Life Scale In Patients With Schizophrenia

  11/3/2014

• Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S Submit New Drug Application In The US For Brexpiprazole For The Treatment Of Schizophrenia And As Adjunctive Therapy For The Treatment Of Major Depressive Disorder

  7/14/2014

• H. Lundbeck A/S's Late Stage Trials For Stroke Failed To Meet Primary Endpoint

  6/27/2014

• H. Lundbeck A/S Release: New Study Results Demonstrate Brintellix® (Vortioxetine) Is Efficacious In Asian Patients Suffering From Depression

  6/26/2014

• H. Lundbeck A/S Completes Acquisition Of Chelsea Therapeutics, Inc.

  6/24/2014

• H. Lundbeck A/S Release: Brintellix® Demonstrated A Statistically Significantly Superior Improvement Compared To Escitalopram In Improving Sexual Functioning In Well Treated Patients Suffering From Depression And Experiencing Treatment-Emergent Sexual Dys

  6/17/2014

• H. Lundbeck A/S Release: New Study Shows That Brintellix® (Vortioxetine) Improves Cognitive Performance And Function In Adult Patients With Major Depression

  6/16/2014

• Chelsea Therapeutics, Inc. Announces The Expiration Of The Hart-Scott-Rodino Waiting Period In Relation To The Proposed Acquisition Of Chelsea Therapeutics By H. Lundbeck A/S

  6/6/2014

• New Incentive Plans In The H. Lundbeck A/S Group

  6/4/2014

• Total Number Of Voting Rights And Share Capital In H. Lundbeck A/S As Of 31 May 2014

  6/2/2014

• H. Lundbeck A/S To Present New Brintellix® Data At The Annual Society Of Clinical Psychopharmacology (ASCP) Meeting

  5/28/2014

• H. Lundbeck A/S Commences Tender Offer For All Outstanding Shares Of Chelsea Therapeutics, Inc.

  5/23/2014